The lipid-reactive oxygen species phenotype of breast cancer. Raman spectroscopy and mapping, PCA and PLSDA for invasive ductal carcinoma and invasive lobular carcinoma. Molecular tumorigenic mechanisms beyond Warburg effect

The Analyst ◽  
2015 ◽  
Vol 140 (7) ◽  
pp. 2121-2133 ◽  
Author(s):  
Jakub Surmacki ◽  
Beata Brozek-Pluska ◽  
Radzislaw Kordek ◽  
Halina Abramczyk

The paper demonstrates that Raman imaging has reached a clinically relevant level in regard to breast cancer diagnosis applications.

1998 ◽  
Vol 67 (1) ◽  
pp. 15-22 ◽  
Author(s):  
Ramasamy Manoharan ◽  
Karen Shafer ◽  
Lev Perelman ◽  
Jun Wu ◽  
Kun Chen ◽  
...  

2017 ◽  
Vol 2017 ◽  
pp. 1-10 ◽  
Author(s):  
Pin Gao ◽  
Bing Han ◽  
Ye Du ◽  
Gang Zhao ◽  
Zhigang Yu ◽  
...  

Raman spectroscopy has been widely used as an important clinical tool for real-time in vivo cancer diagnosis. Raman information can be obtained from whole organisms and tissues, at the cellular level and at the biomolecular level. The aim of this paper is to review the newest developments of Raman spectroscopy in the field of breast cancer diagnosis and treatment. Raman spectroscopy can distinguish malignant tissues from noncancerous/normal tissues and can assess tumor margins or sentinel lymph nodes during an operation. At the cellular level, Raman spectra can be used to monitor the intracellular processes occurring in blood circulation. At the biomolecular level, surface-enhanced Raman spectroscopy techniques may help detect the biomarker on the tumor surface as well as evaluate the efficacy of anticancer drugs. Furthermore, Raman images reveal an inhomogeneous distribution of different compounds, especially proteins, lipids, microcalcifications, and their metabolic products, in cancerous breast tissues. Information about these compounds may further our understanding of the mechanisms of breast cancer.


Author(s):  
Katie Hanna ◽  
Emma Krzoska ◽  
Abeer M. Shaaban ◽  
David Muirhead ◽  
Rasha Abu-Eid ◽  
...  

2008 ◽  
Author(s):  
R. Bitar ◽  
M. A. Martins ◽  
D. Ribeiro ◽  
C. Carvalho ◽  
E. A. P. Santos ◽  
...  

2006 ◽  
Vol 16 (Suppl 1) ◽  
pp. 118-122
Author(s):  
P. F. Escobar ◽  
R. Patrick ◽  
L. Rybicki ◽  
N. Al-Husaini ◽  
C. M. Michener ◽  
...  

The purpose of this study was to quantify and describe nonmammary neoplasms (n-MN), particularly gynecological neoplasms, in a patient population previously diagnosed with breast cancer. Data were collected prospectively in our institutional review board–approved registry for patients diagnosed with infiltrating breast cancer or ductal carcinoma in situ. Patients who developed a second, n-MN were identified; neoplastic site, time to development after breast cancer, and clinical outcomes were recorded. FIGO stage was recorded for patients who developed a gynecological neoplasm. Synchronous bilateral breast cancer was defined as a second, contralateral diagnosis made within 12 months of the first and, similarly, synchronous n-MN were defined as those identified within 1 year of a breast cancer diagnosis. Outcome curves were generated using the method of Kaplan and Meier, and compared using the log-rank test. Of 4126 patients diagnosed with breast cancer, 3% developed a n-MN, the majority of which were nongynecological and asynchronous to the initial breast cancer diagnosis. Three percent of patients diagnosed with breast cancer were diagnosed with a second, n-MN. Among patients who developed a n-MN, most developed a nongynecological cancer more than 1 year after the initial breast cancer diagnosis, and their outcomes were significantly worse than those patients who did not develop a n-MN.


2007 ◽  
Author(s):  
H. Abramczyk ◽  
I. Placek ◽  
B. Brożek-Płuska ◽  
K. Kurczewski ◽  
Z. Morawiec ◽  
...  

2005 ◽  
Author(s):  
Maryann Fitzmaurice ◽  
Abigail A. Haka ◽  
Zoya Volynskaya ◽  
Jason T. Motz ◽  
Joseph A. Gardecki ◽  
...  

2014 ◽  
Vol 5 (7) ◽  
pp. 2435 ◽  
Author(s):  
Qingbo Li ◽  
Qishuo Gao ◽  
Guangjun Zhang

2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Erica B. Friedman ◽  
Jennifer Chun ◽  
Freya Schnabel ◽  
Shira Schwartz ◽  
Sidney Law ◽  
...  

Purpose. In November 2009, the U.S. Preventative Service Task Force (USPSTF) revised their breast cancer screening guidelines. We evaluated the pattern of screening subsequent to the altered guidelines in a cohort of women.Methods. Our database was queried for the following variables: age, race, method of diagnosis, mass palpability, screening frequency, histology, and stage. Statistical analyses were performed using Pearson’s chi-square and Fisher’s exact tests.Results. 1112 women were diagnosed with breast cancer from January 2010 to 2012. The median age at diagnosis was 60 years. Most cancers were detected on mammography (61%). The majority of patients had invasive ductal carcinoma (59%), stage 0 (23%), and stage 1 (50%) cancers. The frequency of screening did not change significantly over time (P=0.30). However, nonregular screeners had an increased risk of being diagnosed with later stage breast cancer (P<0.001) and were more likely to present with a palpable mass compared to regular screeners (56% versus 21%;P<0.001).Conclusions. In our study, screening behavior did not significantly change in the years following the USPSTF guidelines. These results suggest that women who are not screened annually are at increased risk of a delay in breast cancer diagnosis, which may impact treatment options and outcomes.


Sign in / Sign up

Export Citation Format

Share Document